Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co. is an innovative biopharmaceutical enterprise dedicated to the prevention and treatment of infectious diseases. Since its establishment in 2004, specializing in the R&D, production and sales of human vaccines. At present, BCHT owns three manufacturing sites, covering 225,700 square meters in total, on the basis of core technology R&D and industrialization, BCHT has built stable business model, high market recognition and good social image. The company initially offered to the public and successfully listed on the Science and Technology Innovation Board in June, 2021(BCHT Stock Ticker: 688276). Quality is the foundation of the company, innovation research is the driving force of BCHT’s development. In 2008, BCHT successfully launched Varicella Vaccine, Live which owned independent intellectual property, its shelf-life up to 36 months which is the longest one in the world, the market share rank first for many years in China. Influenza Vaccine, Live, Nasal, Freeze-dried (launched in 2020), a novel influenza attenuated live vaccine, is a cooperative project with the WHO, which has been included in Global Action Plan for Influenza Vaccine(GAP), it fills the gap in domestic influenza attenuated live vaccines market and has broad market prospects. The Herpes Zoster Vaccine, Live produced by BCHT was approved for marketing in January 2023 which is the world's first Herpes Zoster Vaccine, Live for people aged at or above 40 years old, it fills the gap in domestic herpes zoster vaccines market, providing a new preventive measure for more eligibles. BCHT—— Devote Biotech Today, Create Health Tomorrow!